293 related articles for article (PubMed ID: 12839875)
1. The general anesthetic propofol increases brain N-arachidonylethanolamine (anandamide) content and inhibits fatty acid amide hydrolase.
Patel S; Wohlfeil ER; Rademacher DJ; Carrier EJ; Perry LJ; Kundu A; Falck JR; Nithipatikom K; Campbell WB; Hillard CJ
Br J Pharmacol; 2003 Jul; 139(5):1005-13. PubMed ID: 12839875
[TBL] [Abstract][Full Text] [Related]
2. Modulation of opioids via protection of anandamide degradation by fatty acid amide hydrolase.
Haller VL; Stevens DL; Welch SP
Eur J Pharmacol; 2008 Dec; 600(1-3):50-8. PubMed ID: 18762181
[TBL] [Abstract][Full Text] [Related]
3. Changes of blood endocannabinoids during anaesthesia: a special case for fatty acid amide hydrolase inhibition by propofol?
Jarzimski C; Karst M; Zoerner AA; Rakers C; May M; Suchy MT; Tsikas D; Krauss JK; Scheinichen D; Jordan J; Engeli S
Br J Clin Pharmacol; 2012 Jul; 74(1):54-9. PubMed ID: 22242687
[TBL] [Abstract][Full Text] [Related]
4. The endogenous cannabinoid anandamide produces delta-9-tetrahydrocannabinol-like discriminative and neurochemical effects that are enhanced by inhibition of fatty acid amide hydrolase but not by inhibition of anandamide transport.
Solinas M; Tanda G; Justinova Z; Wertheim CE; Yasar S; Piomelli D; Vadivel SK; Makriyannis A; Goldberg SR
J Pharmacol Exp Ther; 2007 Apr; 321(1):370-80. PubMed ID: 17210800
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of fatty-acid amide hydrolase accelerates acquisition and extinction rates in a spatial memory task.
Varvel SA; Wise LE; Niyuhire F; Cravatt BF; Lichtman AH
Neuropsychopharmacology; 2007 May; 32(5):1032-41. PubMed ID: 17047668
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of fatty acid amide hydrolase, a key endocannabinoid metabolizing enzyme, by analogues of ibuprofen and indomethacin.
Holt S; Paylor B; Boldrup L; Alajakku K; Vandevoorde S; Sundström A; Cocco MT; Onnis V; Fowler CJ
Eur J Pharmacol; 2007 Jun; 565(1-3):26-36. PubMed ID: 17397826
[TBL] [Abstract][Full Text] [Related]
7. Ex vivo imaging of fatty acid amide hydrolase activity and its inhibition in the mouse brain.
Glaser ST; Gatley SJ; Gifford AN
J Pharmacol Exp Ther; 2006 Mar; 316(3):1088-97. PubMed ID: 16278311
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of fatty acid amide hydrolase and monoacylglycerol lipase by the anandamide uptake inhibitor VDM11: evidence that VDM11 acts as an FAAH substrate.
Vandevoorde S; Fowler CJ
Br J Pharmacol; 2005 Aug; 145(7):885-93. PubMed ID: 15895107
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors.
Dickason-Chesterfield AK; Kidd SR; Moore SA; Schaus JM; Liu B; Nomikos GG; Felder CC
Cell Mol Neurobiol; 2006; 26(4-6):407-23. PubMed ID: 16736384
[TBL] [Abstract][Full Text] [Related]
10. Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates.
Justinova Z; Mangieri RA; Bortolato M; Chefer SI; Mukhin AG; Clapper JR; King AR; Redhi GH; Yasar S; Piomelli D; Goldberg SR
Biol Psychiatry; 2008 Dec; 64(11):930-7. PubMed ID: 18814866
[TBL] [Abstract][Full Text] [Related]
11. Electroconvulsive shock treatment differentially modulates cortical and subcortical endocannabinoid activity.
Hill MN; Barr AM; Ho WS; Carrier EJ; Gorzalka BB; Hillard CJ
J Neurochem; 2007 Oct; 103(1):47-56. PubMed ID: 17561935
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms.
Chang L; Luo L; Palmer JA; Sutton S; Wilson SJ; Barbier AJ; Breitenbucher JG; Chaplan SR; Webb M
Br J Pharmacol; 2006 May; 148(1):102-13. PubMed ID: 16501580
[TBL] [Abstract][Full Text] [Related]
13. Endocannabinoids in the intact retina: 3 H-anandamide uptake, fatty acid amide hydrolase immunoreactivity and hydrolysis of anandamide.
Glaser ST; Deutsch DG; Studholme KM; Zimov S; Yazulla S
Vis Neurosci; 2005; 22(6):693-705. PubMed ID: 16469181
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation.
Fegley D; Gaetani S; Duranti A; Tontini A; Mor M; Tarzia G; Piomelli D
J Pharmacol Exp Ther; 2005 Apr; 313(1):352-8. PubMed ID: 15579492
[TBL] [Abstract][Full Text] [Related]
15. Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors.
Moreira FA; Kaiser N; Monory K; Lutz B
Neuropharmacology; 2008 Jan; 54(1):141-50. PubMed ID: 17709120
[TBL] [Abstract][Full Text] [Related]
16. The novel reversible fatty acid amide hydrolase inhibitor ST4070 increases endocannabinoid brain levels and counteracts neuropathic pain in different animal models.
Caprioli A; Coccurello R; Rapino C; Di Serio S; Di Tommaso M; Vertechy M; Vacca V; Battista N; Pavone F; Maccarrone M; Borsini F
J Pharmacol Exp Ther; 2012 Jul; 342(1):188-95. PubMed ID: 22514334
[TBL] [Abstract][Full Text] [Related]
17. Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172.
Fegley D; Kathuria S; Mercier R; Li C; Goutopoulos A; Makriyannis A; Piomelli D
Proc Natl Acad Sci U S A; 2004 Jun; 101(23):8756-61. PubMed ID: 15138300
[TBL] [Abstract][Full Text] [Related]
18. Involvement of the endocannabinoid system in retinal damage after high intraocular pressure-induced ischemia in rats.
Nucci C; Gasperi V; Tartaglione R; Cerulli A; Terrinoni A; Bari M; De Simone C; Agrò AF; Morrone LA; Corasaniti MT; Bagetta G; Maccarrone M
Invest Ophthalmol Vis Sci; 2007 Jul; 48(7):2997-3004. PubMed ID: 17591864
[TBL] [Abstract][Full Text] [Related]
19. Novel selective and metabolically stable inhibitors of anandamide cellular uptake.
Ortar G; Ligresti A; De Petrocellis L; Morera E; Di Marzo V
Biochem Pharmacol; 2003 May; 65(9):1473-81. PubMed ID: 12732359
[TBL] [Abstract][Full Text] [Related]
20. Control of experimental spasticity by targeting the degradation of endocannabinoids using selective fatty acid amide hydrolase inhibitors.
Pryce G; Cabranes A; Fernández-Ruiz J; Bisogno T; Di Marzo V; Long JZ; Cravatt BF; Giovannoni G; Baker D
Mult Scler; 2013 Dec; 19(14):1896-904. PubMed ID: 23625705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
